Focus on Neuro-
Disease Modeling
Disease modeling with in vitro cellular systems allows researchers to recreate and study mechanisms of neurological disorders in controlled experimental settings. As patient-derived and genetically engineered neuronal models become more human-relevant and more complex, the challenge shifts to establishing robust, reproducible functional phenotypes that can be compared across studies.
In 2026, this focus brings together the newest Disease Modeling material we publish. You’ll find a broad range of content, spanning from expert webinars to additional supporting materials added as they become available. The emphasis is on electrophysiology and readouts from network to subcellular scale, plus practical strategies and shared best practices from the field.
Related Content & Activities
Webinars
.avif)
Tuesday, December 2nd, 2025 | 10:00 CET
01:00 PDT | 04:00 EDT | 17:00 CST | 18:00 JST
MaxWell Webinar with Chengyong Jiang and Yiheng Wang
The webinar covered
- How HD-MEAs can record and characterize photoelectric activity from tellurium nanowire retinal nanoprostheses across visible and near-infrared wavelengths.
- Preclinical use of HD-MEAs to link implant-evoked retinal and cortical activity with restored light sensitivity and behavior in blind animal models.
- The use of HD-MEAs for large-scale ex vivo retinal recordings, enabling population-level monitoring of thousands of neurons for visual scene reconstruction.
- How HD-MEA–generated datasets and analysis pipelines can be used to evaluate and optimize visual prostheses and guide the design of advanced artificial visual systems.
Wednesday, September 24, 2025
17:00 CEST | 08:00 PDT | 11:00 EDT | 23:00 CST | 00:00 JST
MaxWell Webinar with FUJIFILM Cellular Dynamics
The webinar covered
- How the combination of MaxTwo Multi-Well High-Density Multielectrode Arrays (HD-MEA) and FUJIFILM hiPSC-derived neurons has opened new frontiers in investigating neurodegenerative disease mechanisms.
- Comparisons between disease-modeling neuronal lines for Parkinson’s, ALS, and FTD, with healthy donor data highlighting functional differences and disease phenotypes.
- The use of cutting-edge HD-MEA assays under optimized experimental conditions to detect even subtle phenotypic variations and to characterize disease models with greater precision.
Blogs
New Therapeutic Target in the Fight Against ALS
A Nature study presents a human iPSC-derived neuronal network model that reveals how TDP-43 dysfunction drives neurotoxicity in ALS/FTLD and highlights NPTX2 as a promising therapeutic target. Using MaxWell Biosystems' MaxOne HD-MEAs, the team captured high-resolution functional readouts of these networks, supporting detailed characterization from network down to single-cell features.
User Voices
Functional Phenotyping of Neurodevelopmental Disease Models on MaxOne HD-MEA
Interview with Danny McSweeney on how CASK loss-of-function affects neuronal maturation and network synchrony in human induced excitatory neurons. He shares how MaxOne HD-MEA and MaxLab Live enable easy recordings and built-in analysis across genotypes.
Modeling Neurodevelopmental Disorders with Human iPSC Networks on HD-MEA
Dr. Maria Sundberg shares how her team models 16p11.2 deletion using human iPSC-derived neuronal networks. She explains how MaxTwo HD-MEA and MaxLab Live enable detailed network phenotyping and axon tracking.
Dr. Danny McSweeney
“Our team is using the MaxOne HD-MEA System to probe neuronal network synchrony for human induced cortical excitatory neurons across genetic backgrounds. Changes in bursting patterns between wild-type and CASK-knockout genotypes manifest through severe deficits in neuronal burst frequency, mean spikes per burst, and mean inter-burst intervals. To investigate these changes, the MaxOne HD-MEA System provides us an easy, straightforward, and user-friendly system.”
